Previous 10 | Next 10 |
IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer PR Newswire CAESAREA, Israel , Sept. 20, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablat...
IceCure Medical to Join Hands-On Cryoablation Session with ProSense and Host Symposium Led by Renowned Doctors at the CIRCE 2023 Annual Congress PR Newswire ProSense is gaining commercial traction in Europe where it has CE approval for numerous malignant and benign tis...
2023-09-05 09:40:06 ET More on IceCure Medical Seeking Alpha’s Quant Rating on IceCure Medical Historical earnings data for IceCure Medical Financial information for IceCure Medical IceCure Medical Ltd ( ICCM ) Q2 2023 Earnings Call Transcript ...
IceCure Medical's ProSense Cryoablation System Receives Regulatory Approval in Brazil PR Newswire $6.6 million in sales expected in Brazilian market over the next five years per distribution agreement guarantees High level of early interest in ProSense...
IceCure Medical Takes Next Major Initiative as it Prepares to Accelerate the Commercialization of ProSense in U.S. and Canada: Appoints VP of Sales, North America PR Newswire Mr. Shad Good brings nearly 20 years of medical device sales and leadership experience, includ...
IceCure Medical Continues to Experience Growing Global Interest in ProSense: Featured at the 16th Thai Breast Symposium PR Newswire Professor Eisuke Fukuma, who has performed over 600 ProSense breast cancer cryoablation procedures, led a cryoablation symposium with Pr...
2023-08-14 16:05:05 ET IceCure Medical Ltd (ICCM) Q2 2023 Earnings Conference Call August 14, 2023, 10:00 AM ET Company Participants Todd Kehrli - EVC Group, Investor Relations Eyal Shamir - Chief Executive Officer Ronen Tsimerman - Chief Financial Officer and Ch...
2023-08-14 08:43:42 ET IceCure Medical press release ( NASDAQ: ICCM ): 1H GAAP EPS of -$0.168. Revenue of $1.64M (+8.6% Y/Y). For further details see: IceCure Medical GAAP EPS of -$0.168, revenue of $1.64M
IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum PR Newswi...
IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023 IceCure Medical to Report Second Quarter 2023 Financial & Operational Results on August 14, 2023 PR Newswire CAESAREA, Israel , Aug. 7, 2023 /PRNewswire/ ...
News, Short Squeeze, Breakout and More Instantly...
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society PR Newswire Demand for minimally invasive breast cancer treatment was ove...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment fo...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medic...